The Institutional Biosafety Committee (Institutional Biosafety Committee The IBC is an instituti...) is an institutional committee created under the NIH Guidelines to review research involving recombinant DNA and synthetic nucleic acid research. The IBC also reviews all research involving biohazardous materials and has overall oversight and responsibility for the Biosafety program at BU and BMC. The IBC carries out these functions pursuant to requirements set forth by federal, state, and local agencies, as well as BU.
The Institutional Biosafety Committee (IBC) is an institutional committee created under the NIH Guidelines to review research involving recombinant DNA and synthetic nucleic acid research. The IBC also reviews all research involving biohazardous materials and has overall oversight and responsibility for the Biosafety program at BU and BMC.
Please note that if you are performing this type of work without IBC approval, you (and as a result, the institution) are out of compliance with current NIH and local regulations.
IBC Protocol Closure Form
Biological Agents with an Increased Potential to Cause Laboratory Acquired Infection (LAI)
Biological agents deemed to have an increased potential to cause LAI are reviewed by the full IBC and added to the “Biological Agents with Potential to Cause Laboratory Acquired Infection (LAI)” list. The subcommittee also reviews agents proposed on IBC applications that are new to the University prior to approval of the associated IBC protocol. The Research Occupational Health Program (ROHP) provides all individuals listed on projects involving an LAI agent(s) with a special “High Hazard Agent” identification card. This card should be kept on the person and provided to medical care professionals to assist in evaluating for a potential LAI.
Comprehensive Risk-Based Laboratory Inspection Program
Disease Surveillance Reporting
Dual Use Research of Concern
Exposure Control Plan (ECP)
It is the policy of Boston University (BU) to maintain a safe and healthy workplace for all employees, including those who work with human and other potentially infectious materials (OPIM). The provisions of the OSHA Bloodborne Pathogen Standard and Biosafety Manual are the basis for the Boston University compliance program and all employees, contractors and visitors are required to follow the requirements described in this Exposure Control Plan. Boston Medical Center (BMC) has a separate Exposure Control Plan for Hospital employees and operations.
Guidelines for the Use of Human Embryonic Stem Cells
Research involving human embryonic stem cells> is governed by federal and state regulations, NIH Guidelines on Human Stem Cell Research, and Boston University and Boston Medical Center policies. All research that involves the use of human stem cells, human embryos, or their derivatives, must be reviewed and approved by the appropriate oversight committee (e.g. IRB, IBC, and/or IACUC) and the Embryonic Stem Cell Research Oversight Committee (ESCRO) as appropriate, prior to the commencement of the activity.
Inactivated Biological Sample Use Policy
The purpose of the Inactivated Biological Samples Use Policy is to develop a process whereby samples generated as BSL-3 and BSL-4 can be used safely at lower biosafety levels. Inactivation of biological samples renders them noninfectious and therefore they can be handled as Risk Group 1 (RG1) agents under BSL-1 conditions. This policy requires that the use of inactivated, noninfectious biological samples derived from BSL-3 and BSL-4 agents be reviewed and approved by both Environmental Health & Safety (EHS) and the Chair of the IBC prior to being received and used at Boston University (BU) and Boston Medical Center (BMC).
Incident Reporting Requirements for Research Involving Recombinant or Synthetic Nucleic Acid Molecules
The purpose of this policy is to set forth the incident reporting requirements for research involving recombinant or synthetic nucleic acid molecules.
Inoculation of Viral Vectors in Laboratory Rodents
The Inoculation of Viral Vectors in Laboratory Rodents serves as a guide for PIs and indicates the acceptable containment for handling and injection of vectors in the lab and the acceptable animal containment or housing conditions.
Obtaining US Dept. of Agriculture and Centers for Disease Control and Prevention Permits for Importing and Transferring Animal Pathogens and Related Biological Materials
This document provides guidance to the BU researchers about the requirements and resources for bringing animal pathogens whose research are regulated by the USDA and CDC.
Responsibility of the Principal Investigator
Responsibility of the principal investigator for personnel with potential exposure to bloodborne pathogens and other potentially infectious material and other research-related occupational health issues.
Training Policy for IBC
Transgenic Rodent Guidelines
The purpose of this guideline is to identify the types of experiments that involve transgenic rodents that require approval by the Institutional Biosafety Committee (“IBC”) and to describe the Animal Biosafety Level (“ABSL”) containment level to be used, as stipulated in the NIH Guidelines for Research Involving Recombinant DNA Molecules (“NIH Guidelines”).
Verification of Attenuated Biosafety Level 3 (BSL-3) Pathogens Policy
The purpose of this policy is to set forth the procedures for verification of attenuated BSL-3 pathogens before they may be safely handled at the lower biosafety level (“BSL”) designated for the attenuated pathogen.
Below are the forms and policies you will likely need. To quickly find a form or policy in this list please use the Find Function: command+f (mac) or control+f (pc). Or view the full forms and policies libraries under Forms & Policies in the main navigation. Please download and fill out PDFs using Adobe—Acrobat Reader DC is available for free.
- WEB Biological Agents with Potential to Cause Laboratory Acquired Infection (LAI)? Updated February 14, 2017
- WEB Biosafety Manual Updated July 25, 2019
- WEB Comprehensive Risk-Based Laboratory Inspection Program Updated December 1, 2014
- WEB Dual Use Research of Concern (DURC) Policy Updated September 29, 2015
- WEB Exposure Control Plan (ECP) Updated January 1, 2016
- WEB IBC Application (Biological Use Authorization) Updated November 8, 2016
- PDF IBC Protocol Closure Form Updated August 15, 2016
- WEB IBC Training and Health Clearance Requirements Updated May 17, 2016
- WEB Inactivated Biological Sample Use Updated August 15, 2016
- WEB Training Policy for IBC Updated September 29, 2016
- WEB Verification of Attenuated Biosafety Level 3 (BSL-3) Pathogens Policy Updated April 19, 2016
The purpose of this manual is to define the biological safety policies and procedures pertaining to research operations at Boston University. These policies and procedures are designed to safeguard personnel and the environment from biologically hazardous materials and to comply with federal, state, and local regulatory requirements. All BU Principal Investigators and laboratory workers must adhere to the biological safety policies and procedures in the conduct of their research and the management of their laboratories.
For information about specific biological safety programs for operations not covered in this manual, contact the Institutional Biosafety Committee office or the Biological Safety Officer.
Table of Contents
- Chapter 1: Biological Safety Program: Purpose, Scope, and Responsibilities
- Chapter 2: Approval of Research Projects
- Chapter 3: List of Regulations and Guidelines
- Chapter 4: Biosafety Principles
- Chapter 5: Laboratory Biosafety Practices
- Chapter 6: Laboratory Training
- Chapter 7: Decontamination and Sterilization
- Chapter 8: Biohazardous Spill Response
- Chapter 9: Biohazardous and Medical Waste Disposal
- Chapter 10: Center for Disease Control /United States Department of Agriculture Select Agents
- Chapter 11: Transportation of Biological Materials
- Appendix A: IBC Application Forms / Biological Use Authorization (BUA)
- Appendix B: Import and Export of Infectious Biological Agents
- Appendix C: Laboratory Ventilation and Containment for Biosafety
- Appendix D: Autoclave Quality Assurance Program
- Appendix E: Biosafety Level 2 (BSL-2) Requirements
- Appendix F: Biosafety Level 3 (BSL-3) Requirements and Practices
- Appendix G: Guidelines for Work with Toxins of Biological Origin
- Appendix H: List of Biological Agents with the Potential to Cause Laboratory Acquired Infection (LAI)
- Appendix I: Prion Research/Creutzfeldt-Jacob Disease (CJD) Guidelines
- Appendix J: Summary of Requirements for Biosafety Levels
- Appendix K: Summary of Requirements for Animal Biosafety Levels
- Appendix L: Bloodborne Pathogen Standard
- Appendix M: Working Safely with Animals
- Appendix N: Procedures for Working in an Animal Biosafety Level 2 (ABSL-2) Facility at BU
- Appendix O: Policy for Verifying the Identity of Attenuated Pathogens
- Appendix P: Boston Public Health Commission Requirements
- Appendix Q: ROHP Medical Surveillance Program
- Appendix R: Laboratory and Equipment Decontamination Procedures
- Appendix S: Laboratory Door Signage
- Appendix T: Boston University Research Compliance Policy on Disease Surveillance and Reporting for High-Risk Agents
- Appendix U: Institutional Biosafety Committee Oversight Program
- Appendix V:Criteria for Development of Standard Operating Procedures (SOP)
Meeting Dates and Deadlines
|Submission Deadline||Meeting Date|
|December 18, 2018||January 22, 2019|
|January 29, 2019||February 19, 2019|
|February 26, 2019||March 19, 2019|
|March 26, 2019||April 16, 2019|
|April 30, 2019||May 21, 2019|
|May 28, 2019||June 18, 2019|
|June 25, 2019||July 16, 2019|
|July 30, 2019||August 20, 2019|
|August 27, 2019||September 17, 2019|
|September 24, 2019||October 15, 2019|
|October 22, 2019||November 19, 2019|
|November 26, 2019||December 17, 2019|
*Applications must be received before the submission deadline to allow time for a detailed and complete review.
**Meetings may be cancelled if too few applications are submitted in a given month. If too many applications are submitted, those received latest will be reviewed at the next scheduled meeting.No Results Found
If you have questions or need help, please contact one of the specialists. You can email them directly or feel free to call. Office information can be found below.
Executive Director, Research Integrity
617-358-7891 (BUMC); 617-358-3867 (CRC)Email Me
Sajal K. Ghosh
Senior Compliance Specialist, Safety Committees Program
Compliance Specialist, Animal Welfare Program/Safety Committees Program
(617) 358-7889Email Me